Companies
Danimer Scientific
its Nodax PHA, the first marine-biodegradable certified resin, supplied Mars, PepsiCo and Nestlé, but after a 2020 SPAC peaked near an 8 billion dollar valuation the firm filed Chapter 11 in March 2025 under 402 million dollars of debt, and Teknor Apex acquired its assets in February 2026 for about 19 million dollars.
- Country
- United States
- Ticker
- DNMR
Coverage
| CN | EU | US | |
|---|---|---|---|
| polymers-materials | ✓ | ✓ | ✓ |
Regulatorsepareachefsa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Approximately $380 million raised through a December 2020 SPAC merger | elevenflo.com · businesswire.com · plasticsnews.com |
| Capacity | Approximately 65 million pounds of annual nameplate capacity at Kentucky facility as of 2022; planned Bainbridge Greenfield capacity of 125 million pounds, though construction paused in 2024 | danimerscientific.com |
| Certification | Nodax PHA certified as marine, freshwater, soil biodegradable, and industrially/home compostable by TUV AUSTRIA; OK biobased certified | danimerscientific.com · nestle.com · sec.gov |
| Regulatory approval | FDA approved for food-contact applications | danimerscientific.com · sec.gov |
| Production site | Facilities in Winchester, Kentucky and Bainbridge, Georgia | elevenflo.com · ir.danimerscientific.com · bccresearch.com |
| Headcount | 82 employees as of March 2025 bankruptcy filing, reduced from 170 prior to restructuring | bondoro.com · elevenflo.com |
| Revenue | $51.8 million for the full year 2024 | elevenflo.com |
Independent sources: bccresearch.com · bondoro.com · businesswire.com · elevenflo.com · nestle.com · plasticsnews.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biopolymers & bioplastics (PLA, PHA, PBAT & bio-PE/PP) | polymers-materials | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.